Enlivex Therapeutics Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 29.07 million compared to USD 31.06 million a year ago. Basic loss per share from continuing operations was USD 1.56 compared to USD 1.69 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.428 USD | -1.54% | -7.90% | -47.13% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.13% | 27.28M | |
+7.42% | 111B | |
+11.21% | 106B | |
-12.55% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.77% | 16.81B | |
+37.38% | 12.54B | |
-24.10% | 8.09B |
- Stock Market
- Equities
- ENLV Stock
- News Enlivex Therapeutics Ltd.
- Enlivex Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023